Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP

Condition(s) studied

Investigational drug(s) / intervention(s)

Dutasteride: Patients in the study group received 0.5 mg/day of dutasteride for at least 6 months before surgery as part of their routine BPH treatment.

Holmium Laser Enucleation of the Prostate (HoLEP): Standard HoLEP procedure performed for the surgical treatment of benign prostatic hyperplasia.

Study summary

This study aims to investigate the effects of long-term dutasteride use (a 5-alpha reductase inhibitor) on surgical outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH).

While some studies suggest that short-term use of these medications can reduce bleeding during surgery, there is limited data on the impact of chronic, long-term use (at least 6 months) specifically during the HoLEP procedure.

The researchers will retrospectively analyze patient records to compare two groups: those who used dutasteride for 6 months or longer before surgery, and those who did not use any 5-alpha reductase inhibitors. The primary focus is to determine whether long-term dutasteride treatment leads to a significant difference in surgical bleeding (measured by hemoglobin drop), operation time, and the efficiency of removing prostate tissue (morcellation). The findings will help surgeons better understand how preoperative medication history influences the technical aspects of HoLEP surgery.

Eligibility

Primary outcome measure(s)

• Change in Hemoglobin Levels (Hemoglobin Drop) — From the time of hospital admission (preoperative) up to 24 hours after surgery.
  The difference between preoperative hemoglobin levels and postoperative (first 24 hours) hemoglobin levels to assess surgical bleeding.

Trial sites (1)

More Ankara City Hospital Bilkent trials in Turkey

Other trials for the same condition